Form 4: Health Catalyst Director Larson-Green Receives 20,807 Restricted Stock Units

Julie Larson-Green, a director at Health Catalyst, Inc., was granted 20,807 Restricted Stock Units (RSUs) on June 13, 2024, according to a Form 4 filing.

Summary

• On June 13, 2024, Julie Larson-Green, a director of Health Catalyst, Inc. (HCAT), received an award of 20,807 Restricted Stock Units (RSUs).
• These RSUs were granted pursuant to the company's 2019 Plan.
• Each RSU represents a contingent right to receive one share of Health Catalyst's common stock.
• The RSUs will fully vest on the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the next Annual Meeting of the Issuer's Stockholders.
• Following this transaction, Larson-Green directly owns 65,238 shares of Health Catalyst common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The RSU grant is a standard practice and indicates continued investment in key personnel. There are no explicit negative indicators.

Positives

• The grant of RSUs aligns the director's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Future Outlook

The document does not contain specific forward-looking statements, but the RSU grant suggests an ongoing commitment to incentivizing key personnel.

Industry Context

This type of equity compensation is common in the tech industry to attract and retain talent and align their interests with company performance.

Comparison to Industry Standards

• RSU grants are a standard form of executive compensation, particularly in technology and healthcare companies like Health Catalyst.
• Companies such as Cerner (now Oracle Health) and Allscripts also utilize RSUs as part of their compensation packages for directors and executives.
• The vesting schedule of one year or the next annual meeting is fairly typical for RSU grants.

Stakeholder Impact

• The RSU grant could have a slightly positive impact on shareholder sentiment as it aligns director interests with company performance.
• The director is incentivized to increase the value of the company.

Key Dates